Positive 90-day GLP toxicology study results in non-rodents
Filed with ASX · · 2 pages · English
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Quarterly Activities/Appendix 4C Cash Flow Report
- Binding Commitments Received for a $4 Million Placement
- Trading Halt
- Neurotech receives $4.73m R&D Tax Incentive Refund
Later from Neurotech International
- Appendix 4D & Half Year Report
- NTI initiates First Clinical Site for Phase 3 ASD Trial
- NTI secures Notices of Allowance for US patent applications
- US FDA clears IND for NTI164
- Neurotech secures $3.15 million R&D tax incentive loan
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International